News

Private Payrolls Increased More Than Expected

Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in Chi

Strong demand but earnings fall short

Beyond obvious strength in Healthcare, we're starting to see "green shoots" in industries that a year ago were seeing negative growth.

Novo Nordisk shares climbed Wednesday after the Danish drugmaker beat estimates with its latest quarterly results.

Strong Wegovy demand lifted revenue as earnings missed estimates

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 1% and the actively traded

News of the day for May 6, 2026

Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.

Novo Nordisk (NYSE:NVO) raised its full-year guidance on Wednesday, citing continued strong demand for its obesity and diabetes treatments despite softer underlying first-quarter results caused by pricing pressure. The pharmaceutical group said it now expects adjusted sales and operating profit for 2026 to decline between 4% and 12% at constant exchange rates, representing a narrower contraction than previously anticipated and reflecting stronger expectations for its GLP-1 treatment portfolio.

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.

Shares in Advanced Micro Devices and Intel surge after AMD CEO Lisa Su flags surging demand for central processing units.

↗️Advanced Micro Devices (AMD): Shares of the chipmaker soared premarket after it reported stronger sales and logged higher profit. Shares of its peer Super Micro Computer Inc. (SMCI) also jumped premarket.

May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.

VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.

Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report. For ... Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Competition from Eli Lilly puts pressure on margins despite strong early uptake

Novo Nordisk A/S (NYSE:NVO) is experiencing strong early uptake for its new weight-loss pill, but intensifying competition with U. S.

Novo Nordisk's oral semaglutide for obesity is gaining traction as demand picks up for the new pill version of Ozempic. The FDA has proposed restricting compounding of GLP-1 drugs such as semaglutide, which could support branded products. Rival Eli Lilly is facing delays to its own obesity pill, giving Novo Nordisk more room to build its lead in oral GLP-1 therapies. Novo Nordisk is responding with new leadership, pricing changes, and cost reductions to sharpen its obesity drug focus. Novo...

NVO heads into Q1 with strong GLP-1 drug demand and new Wegovy pill rollout, but pricing pressure, weak guidance and Eli Lilly rivalry weigh on outlook.

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

The Food and Drug Administration has recorded two ‘serious’ cases in patients taking Eli Lilly’s weight-loss pill.

Investing.com -- Eli Lilly and Company (NYSE:LLY) fell 3% Monday, while Novo Nordisk (NYSE:NVO) rose 2% after Evercore ISI analyst Umer Raffat flagged a liver case in the FDA adverse event database that has "potential to create confusion" for Eli Lilly.

First quarter earnings season is in full swing, with a full slate of semiconductor and consumer companies slated to report results.

Ozempic oral pill will be produced entirely in the US and distributed through more than 70,000 pharmacies in the US.